231 related articles for article (PubMed ID: 11429005)
1. Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients.
Turgeon N; Hovingh GK; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
Transpl Infect Dis; 2000 Mar; 2(1):15-21. PubMed ID: 11429005
[TBL] [Abstract][Full Text] [Related]
2. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
[TBL] [Abstract][Full Text] [Related]
3. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.
Turgeon N; Fishman JA; Doran M; Basgoz N; Tolkoff-Rubin NE; Cosimi AB; Rubin RH
Transpl Infect Dis; 2000 Mar; 2(1):2-10. PubMed ID: 11429003
[TBL] [Abstract][Full Text] [Related]
4. Single-center, real-world experience with granulocyte colony-stimulating factor for management of leukopenia following kidney transplantation.
Hamel S; Kuo V; Sawinski D; Johnson D; Bloom RD; Bleicher M; Goral S; Lim MA; Trofe-Clark J
Clin Transplant; 2019 Jun; 33(6):e13541. PubMed ID: 30887581
[TBL] [Abstract][Full Text] [Related]
5. Management of leukopenia in kidney and pancreas transplant recipients.
Hartmann EL; Gatesman M; Roskopf-Somerville J; Stratta R; Farney A; Sundberg A
Clin Transplant; 2008; 22(6):822-8. PubMed ID: 19040562
[TBL] [Abstract][Full Text] [Related]
6. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
Khan S; Sullivan T; Ali M; Dunn D; Patel G; Huprikar S
Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK
Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte colony-stimulating factor therapy is associated with a reduced incidence of acute rejection episodes or allograft vasculopathy in heart transplant recipients.
Vrtovec B; Haddad F; Pham M; Deuse T; Fearon WF; Schrepfer S; Leon S; Vu T; Valantine H; Hunt SA
Transplant Proc; 2013; 45(6):2406-9. PubMed ID: 23953556
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human granulocyte colony-stimulating factor after kidney transplantation: a retrospective analysis to evaluate the benefit or risk of immunostimulation.
Schmaldienst S; Bekesi G; Deicher R; Franz M; Hörl WH; Pohanka E
Transplantation; 2000 Feb; 69(4):527-31. PubMed ID: 10708106
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
[TBL] [Abstract][Full Text] [Related]
11. Randomized, placebo-controlled, double-blind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients.
Winston DJ; Foster PF; Somberg KA; Busuttil RW; Levy MF; Sheiner PA; Reddy KR; Fotheringham N; Armstrong M; Logan E
Transplantation; 1999 Nov; 68(9):1298-304. PubMed ID: 10573067
[TBL] [Abstract][Full Text] [Related]
12. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients.
Peddi VR; Hariharan S; Schroeder TJ; First MR
Clin Transplant; 1996 Feb; 10(1 Pt 1):20-3. PubMed ID: 8652892
[TBL] [Abstract][Full Text] [Related]
13. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir.
Dunn DL; Mayoral JL; Gillingham KJ; Loeffler CM; Brayman KL; Kramer MA; Erice A; Balfour HH; Fletcher CV; Bolman RM
Transplantation; 1991 Jan; 51(1):98-106. PubMed ID: 1846255
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
15. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
16. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.
Taber DJ; Ashcraft E; Baillie GM; Berkman S; Rogers J; Baliga PK; Rajagopalan PR; Lin A; Emovon O; Afzal F; Chavin KD
Transpl Infect Dis; 2004 Sep; 6(3):101-9. PubMed ID: 15569225
[TBL] [Abstract][Full Text] [Related]
17. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
Halim MA; Al-Otaibi T; Gheith O; Adel H; Mosaad A; Hasaneen AA; Zakaria Z; Makkeya Y; Said T; Nair P
Exp Clin Transplant; 2016 Oct; 14(5):526-534. PubMed ID: 27310254
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
Park JM; Lake KD; Arenas JD; Fontana RJ
Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
